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MAIN TEXT 
 To the Editor, 
 Leukocyte adhesion deficiency type III (LAD-III) is a recessive autosomal condition 
characterized by bleeding events and life-threatening infections. This condition is due to 
variations in the FERMT3 gene (encoding the kindlin-3 protein) that impair integrin function. 
Less than 40 LAD-III cases have been reported.1 The primary treatment for this condition is 
early hematopoietic stem cell transplantation (HSCT), which is however associated with 
severe complications and high rates of treatment-related mortality. 
 In 2011, our team described a patient of gypsy ethnicity carrying a novel bi-allelic 
FERMT3 variant.2 Herein, we discuss the long-term data regarding innovative therapeutic 
management of the disorder involving hemostatic and antimicrobial treatment, without HSCT. 
We performed a systematic literature review, which provides exhaustive data concerning 
complications, therapeutic strategies and prognosis of LAD-III. Furthermore, we investigated 
in vitro the effect of recombinant factor VIIa (rFVIIa) on kindlin-3-deficient platelet 
aggregation. 
 The patient was included in the study after informed written consent was obtained 
from his parents, in accordance with the Declaration of Helsinki. The systematic review was 
included in the PROSPERO international prospective register (registration number 
CRD42017064092). The electronic databases MEDLINE, Cochrane Library and Web of 
Science were included in the literature search according to the strategy described on the 
PROSPERO website (http://www.crd.york.ac.uk/prospero). The flow diagram of the 
systematic review is presented in Figure 1A. Thirty-four LAD-III patients were included in the 
review. Data from the systematic review are compiled in Figure 1B-E and Supplemental 
Table. 
 The patient presented with bleeding symptoms starting at birth, as is common in most 
LAD-III patients. He constantly suffered from mild to moderate mucocutaneous bleeding 
(petechiae, buccal hemorrhaging and epistaxis). A total of 71% of reported LAD-III cases 
presented with mucocutaneous bleeding, which constitutes a hallmark of the disease (Figure 
1B, top). The patient’s medical history involved severe bleeding episodes (traumatic penile 
hematoma, hematuria and traumatic bleeding of the tongue). The patient’s ISTH-BAT 
bleeding score was 13. The LAD-III bleeding phenotype may be more severe than that of 
Glanzmann thrombasthenia.3 Indeed, intracranial hemorrhage, gastrointestinal bleeding and 
pulmonary bleeding occurred in 15%, 15% and 6% of reported patients, respectively (Figure 
1B, top). The management of these complications remains very challenging, as illustrated by 
the reports of three deaths due to bleeding complications.  
 Erythrocyte and platelet transfusions were performed in >90% of LAD-III cases, 
constituting a pivotal treatment for bleeding events (Figure 1B, bottom). Some patients 
received >20 erythrocyte transfusions and >50 platelet transfusions per year.4 Our patient 
received only one platelet transfusion, which may be due to the use of rFVIIa as a first-line 
treatment for severe bleeding as well as a preventive treatment in high-risk situations (off-
label use). Ten doses of 90-120 μg/kg rFVIIa were successfully administered to treat penile 
hematoma (one dose), tongue bleeding (five doses) and three preventive circumstances 
(one to two doses; dental surgeries). The first dose of rFVIIa was administered at 17 months 
of age. This treatment has not been previously reported in LAD-III cases. Tranexamic acid 
was used in 8% of reported cases. Our patient received this antifibrinolytic drug as a long-
term prophylaxis, which has never been reported in LAD-III cases. This treatment has been 
used from the age of three at a dose of 25 mg/kg/day divided in three oral doses. 
 The clinical efficacy of rFVIIa to control bleeding in Glanzmann thrombasthenia 
patients has been clearly demonstrated,3 although the mechanism of action of rFVIIa in this 
disease is not fully understood. Direct activation of Factor X on the platelet surface by rFVIIa 
may improve local thrombin generation.5 Furthermore, rFVIIa treatment restores aggregation 
of Glanzmann thrombasthenia platelets in vitro.6 We observed rFVIIa-mediated platelet 
aggregation for αIIbβ3-inhibited platelets and kindlin-3-deficient platelets (Figures 2AB), 
thereby possibly explaining the clinical efficacy of rFVIIa in LAD-III patients. Platelet 
aggregates were analyzed using transmission electron microscopy (Figure 2C). The 
interplatelet distance within rFVIIa-mediated aggregates of kindlin-3-deficient platelets was 
increased and less regular compared with that of control platelet aggregates (mean ± 
standard deviation 359 ± 373 nm, n=31 versus 59 ± 18 nm, n=59, respectively; n referring to 
the number of interplatelet distances measured). However, interplatelet close interactions 
(<100 nm) were also observed.  
Platelet glycoprotein VI (GPVI) has recently been shown to bind to immobilized fibrin.7 
We hypothesized that GPVI-fibrin interactions may mediate the aggregation of kindlin-3-
deficient platelets in our model. In the presence of a fibrin generating system (prothrombin 
complex concentrate, fibrinogen, rFVIIa), washed kindlin-3-deficient platelets fully 
aggregated in response to collagen or TRAP-6 (Figure 2B). This aggregation was impeded if 
fibrin polymerization was inhibited by the Gly-Pro-Arg-Pro peptide (Figure 2B). Blocking 
GPVI using the anti-GPVI Fab fragment 9O128 inhibited collagen-induced aggregation of the 
kindlin-3-deficient platelets, which correlates with the fact that GPVI represents the receptor 
for platelet activation by collagen. However, the anti-GPVI Fab fragment 9O12, which was 
shown to inhibit GPVI-fibrin interactions,7 did not prevent rFVIIa-mediated aggregation upon 
TRAP-6 stimulation. This suggests that GPVI-fibrin interactions were not involved in this 
response (Figure 2B). Dependence on rFVIIa-mediated fibrin generation may explain the 
increased aggregation lag-time compared with that observed upon activation of normal 
platelets (Figure 2AB). The use of collagen in this model probably results in 
collagen/thrombin double stimulation, which is known to strongly promote the formation of 
procoagulant platelets.9 This may explain the difference in aggregation lag-time following 
collagen or TRAP-6 stimulation (Figure 2B). 
 Regarding infections, the patient was treated with trimethoprim/sulfamethoxazole at 
five months of age for probable Pneumocystis jirovecii pneumonia, as reported for other 
LAD-III patients. Thereafter, preventive antibiotics (trimethoprim/sulfamethoxazole and 
itraconazole) were initiated. The patient did not suffer from additional severe infections, even 
after itraconazole was discontinued at 3.5 years of age. Severe bacterial infections have 
been reported in LAD-III patients, including bacteremias (47%), pulmonary infections (47%), 
omphalitis (12%) and other soft tissue infections (32%) (Figure 1C, top). Furthermore, fungal 
infections, such as Aspergillus pneumonia and Fusarium sepsis have been reported. Few 
authors have reported the use of bacterial or fungal prophylaxis in LAD-III patients (22%) 
(Figure 1C, bottom). Although these data emphasize individual variability, systematic 
antifungal and antibacterial prophylaxis should be considered for LAD-III patients. 
 With sustained hypogammaglobulinemia, our patient required long-term gamma 
globulin replacement at 10 months of age. This treatment has rarely been reported in the 
literature (17%; Figure 1C, bottom). Gamma globulin levels were only evaluated in six cases. 
Two of these patients suffered from hypogammaglobulinemia.10,11 These patients presented 
no severe infection while undergoing gamma globulin replacement, and one patient 
developed severe sepsis a few weeks after discontinuing replacement therapy.11 In some 
patients, a defect in the adaptive immune response is thus an aspect of LAD-III, which 
suggests that kindlin-3 plays a role in B-cell biology.11 Gamma globulin levels must be 
systematically evaluated, as long-term gamma globulin replacement may effectively prevent 
severe infections in LAD-III patients with hypogammaglobulinemia. 
 HSCT has been reported as the only curative therapy for LAD-III.1 Indeed, several 
groups have reported long-term, disease-free LAD-III survivors after HSCT. This therapy 
option has been applied in 68% of cases (Figure 1D). Furthermore, the reported survival of 
non-transplanted patients is relatively low (55%) (Figure 1E). Lethality is probably 
underestimated due to cases who died prior to diagnosis. Indeed, several siblings of LAD-III 
patients have died during the first months of life due to bleeding or infection. However, the 
mortality rate was 22% among transplanted patients (Figures 1D-E), and all deaths were 
directly due to HSCT complications. Severe complications were reported in 48% of cases, 
e.g., graft failure, sinusoidal obstruction syndrome or graft-versus-host disease (Figure 1D). 
Notably, 32% of patients had osteopetrosis, which likely compromises engraftment. 
Therefore, balancing of the risk of rejection and toxicity is challenging in this disease. This 
may explain that the appropriate type of conditioning regimen remains controversial (Figure 
1D). Furthermore, LAD-III survivors treated without HSCT have been reported.12 Regarding 
our patient, optimized treatment to manage bleeding and infection without HSCT appears to 
be an efficient therapeutic approach, with no significant adverse events. Indeed, this strategy 
led to a favorable outcome after a 10-year follow-up. Our patient exhibits normal growth and 
development and has integrated into a standard school system. This approach may also 
apply to other LAD-III patients. 
This study provides new insights regarding the complications, management and 
prognosis of LAD-III. Notably, we report the first effective use of rFVIIa to treat and prevent 
bleeding in a LAD-III patient, which was supported by in vitro platelet ultrastructural and 
aggregation data. Our results suggest that rFVIIa activity is platelet activation-dependent, 
fibrin-dependent and independent of GPVI-fibrin interaction. International registry and cohort 
studies should be implemented to identify prognostic factors that could guide therapeutic 
strategies for LAD-III.  
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FIGURE LEGENDS 
Figure 1: Systematic review of leukocyte adhesion deficiency type III 
complications, treatments and outcome 
(A) Flow diagram of the systematic review. The number or records included or excluded is 
indicated at each step. Twenty-seven records reporting data from 34 patients were ultimately 
included in the analysis. The previous report from our group2 was excluded.  
(B) Prevalence of bleeding events with regards to topography (top; n=27) and associated 
treatments (bottom; n=24) among LAD-III patients reported in the literature. Frequency of 
vaginal bleeding was calculated for female patients. CNS: central nervous system; TF: 
transfusion. 
(C) Prevalence of infections with regards to topography / type (top; n=27) and associated 
treatments (bottom; n=18) among LAD-III patients reported in the literature. ATB: antibiotics; 
Ig: immunoglobulin. 
 (D): Description of LAD-III patients treated with hematopoietic stem cell transplantation 
(HSCT). The percentage of patients treated with HSCT was calculated for all reported LAD-
III patients (n=34). The frequency of conditioning regimens and HSCT-related complications 
was calculated for transplanted patients (n=23). Some patients underwent two HSCTs with 
different types of conditioning regimen, thus the sum of the conditioning regimen frequencies 
exceeds 100%. Conditioning regimen intensity was defined as previously reported.13 
(E) Survival rate of reported LAD-III patients. HSCT: hematopoietic stem cell transplantation. 
Figure 2: rFVIIa-mediated aggregation of αIIbβ3-inhibited and kindlin-3-
deficient platelets 
(A-B) Light transmission aggregometry. Washed platelets were prepared from citrated blood 
samples obtained by venipuncture and resuspended in Hepes-Tyrode buffer at pH 7.4 (final 
platelet concentration = 200 x 109/l). The platelet suspension was recalcified with 3 mM 
CaCl2. Aggregation of (A) control platelets pretreated for 10 minutes with the αIIbβ3 inhibitor 
tirofiban (50 µg/ml; Sigma-Aldrich) and (B) kindlin-3-deficient platelets was monitored using 
an PAP-8E aggregometer (Bio/Data Corporation) at 37°C, with a stir speed of 900 rpm. The 
platelets were activated with 4 µg/mL collagen (Hyphen) or 20 µM TRAP-6 (SFLLRN; 
PolyPeptide Group). The effect of (1) a fibrin-generating system consisting of fibrinogen (fg; 
50 µg/ml), factor II (0.13 UI/ml), factor VII (0.07 UI/ml), factor IX (0.16 UI/ml), factor X (0.18 
UI/ml), and recombinant factor VIIa (rFVIIa; 1.2 µg/ml; Novoseven®, NovoNordisk), (2) the 
fibrin polymerization inhibitor Gly-Pro-Arg-Pro (GPRP; 5 mM; AnaSpec/Eurogentec), and (3) 
the anti-GPVI blocking Fab 9O128 (30 µg/ml) was evaluated. Factors II, VII, IX, and X – i.e., 
prothrombin complex concentrate (PCC) – were prepared using a Confidex® solution (CSL 
Behring GmbH). The data are representative of two independent experiments for the 
patient’s platelets and four independent experiments for the tirofiban-treated control platelets. 
(C) Representative transmission electron microscopy images of platelet aggregate ultrathin 
sections. The aggregates of control platelets (left) and kindlin-3-deficient platelets in the 
presence of the fibrin-generating system described above (right) were fixed and prepared as 
previously described14 after a 10 min stimulation with 4 µg/ml collagen. Images of the same 
field acquired at higher magnification are shown at the bottom. Scale bar, 1 µm (top) and 200 
nm (bottom). 

SUPPLEMENTAL MATERIAL 
Long-term management of leukocyte adhesion deficiency 
type III without hematopoietic stem cell transplantation 
 
Supplemental Table: Complications, therapeutic management and outcome of previously reported LAD-III patients  
FERMT3  
alteration 
Gender 
(M / F) 
HSCT 
Age at conditioning, donor, conditioning 
regimen, complications, outcome 
Bleeding complications  Infections Survival 
(Y / N) 
Supplemental 
references 
Description Management  Description Management 
c.48G>A 
p.W16X 
M Yes 
Mucosal bleedings, 
CNS bleeding 
RBC TF  Lymphadenitis, Recurrent infections NA Y 1 
c.48G>A 
p.W16X 
F Yes 
Mucocutaneous 
bleedings, CNS 
bleeding 
Platelet TF  Recurrent infections NA Y 1 
c.687G>A 
p.W229X 
NA Yes, † 
Moderate bleeding 
tendency 
NA  NA NA N 2,3 
c.687G>A 
p.W229X 
M 
6 years, MMRD, RIC 
(alemtuzumab/Bu/Flu/Mel), † 
Mucocutaneous 
bleedings 
Life-threatening 
bleedings 
Platelet and RBC 
TF, Tranexamic 
acid 
 
Omphalitis, Recurrent soft tissue infections, 
Bacteremia (Staphylococcus), 
Osteomyelitis, CMV viremia, Disseminated 
fungal infection (†) 
ATB therapy, granulocyte 
TF, surgical debridement, 
ATB prophylaxis, 
ganciclovir, antifungal 
treatment 
N 4,5 
c.687G>A 
p.W229X 
F 
21 and 51 months, MMUUCBD 5/6 and 
MMUD 8/10, MAC (Bu/Cy/ATG) and RIC 
(Flu/Treo/TT/ATG), GvHD (Grade IV), good 
outcome 
Mucocutaneous 
bleedings, 
Gastrointestinal 
bleedings 
Platelet and RBC 
TF 
 
Pneumocystis pulmonary infection, 
Recurrent CMV viremia 
ATB therapy, ganciclovir Y 5 
c.687G>A 
p.W229X 
M 
12 months, MRD, RIC 
(Flu/Treo/TT/Alemtuzumab), no GvHD, good 
outcome 
Cutaneous bleeding 
Platelet and RBC 
TF 
 
Recurrent pulmonary infections, Cellulitis, 
Gangrene, Deep-seated abscesses, 
Intestinal infection, Bacteremia 
(Pseudomonas, Klebsiella) 
ATB therapy, amputation Y 5 
c.[922G>A;1287delT] 
p.[G308R;E430Rfs*3] 
F 
8 months, MMUUCBD 5/6, RIC 
(Flu/Bu/Cy/rabbit ATG), skin and gut GvHD 
(Grade III), good outcome 
Gastrointestinal 
bleedings, Traumatic 
hematomas 
Platelet and RBC 
TF 
 
Necrotizing enterocolitis, RSV pulmonary 
infection, Urinary tract infection (E. coli, P. 
aeruginosa), Bacteremia (S. aureus) 
ATB therapy, Partial bowel 
resection 
Y  6,7 
c.1324-1G>A 
splice variant 
F No HSCT 
Joint bleedings (knee, 
elbow), 
Mucocutaneous 
bleedings 
NA  
Pulmonary infection, Otitis media, Arthritis, 
Recurrent CMV viremia 
ATB therapy, ganciclovir Y 8 
c.1438C>T 
p.Q480X 
M 8 months, MRD, Good outcome Mucosal bleedings NA  
Omphalitis, Urachal duct cyst infection, Soft 
tissue infection, Bacteremia 
(Staphylococcus), Pneumocystis pulmonary 
infection, Oral candidiasis; Urinary tract 
infection 
ATB therapy Y 9–11 
c.1438C>T 
p.Q480X 
M 15 weeks, Good outcome Cutaneous bleedings NA  
Oral candidiasis, Omphalitis, Bacteremia 
(Staphylococcus) 
ATB therapy Y 9 
c.1537C>T 
p.R513X 
F MUD, GvHD (†) 
Gastrointestinal 
bleedings, Hematuria, 
Mucosal bleedings 
Platelet and RBC 
TF 
 
Recurrent pulmonary infections, Bacteremia 
(†) 
NA N 12 
c.1537C>T 
p.R513X 
M Good outcome 
Gastrointestinal 
bleedings, Hematuria, 
Mucosal bleedings 
Platelet and RBC 
TF 
 Recurrent pulmonary infections NA Y 12 
c.1537C>T 
p.R513X 
M No HSCT 
Severe 
mucocutaneous 
bleedings 
Platelet and RBC 
TF 
 Bacteremia and fungemia NA N 13 
c.1537C>T 
p.R513X 
M No HSCT 
Cutaneous bleedings, 
Pulmonary 
hemorrhage (†) 
NA  
Recurrent pulmonary infections, Intestinal 
infection, Bacteremia (P. aeruginosa), Oral 
candidiasis 
NA N 13,14 
c.1537C>T 
p.R513X 
F 
3.5 years, MMRD x 2, RIC (Flu/Mel/TT/rabbit 
ATG) and MAC (Bu/Cy/TLNI), no engraftment 
Severe bleeding 
tendency 
Platelet and RBC 
TF 
 
Recurrent pulmonary infections, buccal 
infection (P. aeruginosa) 
ATB therapy Y 13–15 
c.1537C>T 
p.R513X 
F No HSCT 
Mucocutaneous 
bleedings, Pulmonary 
hemorrhage (†) 
Platelet and RBC 
TF 
 
Pulmonary infections, Otitis media, 
Bacteremia (†) 
ATB therapy N 13,14 
c.1537C>T 
p.R513X 
M 13 years, MUD, † 
Mucosal bleedings, 
Postoperative thoracic 
bleeding 
Platelet and RBC 
TF 
 
Perianal abscesses, Pulmonary infection, 
Bacteremia (P. aeruginosa), Mediastinal 
mass 
ATB therapy, ATB 
prophylaxis, Ig replacement 
therapy, granulocyte TF, 
voriconazole 
N 2,3,16,17 
c.1537C>T 
p.R513X 
M 4 years, Good outcome 
Severe bleeding 
tendency, Cutaneous 
bleedings 
Platelet and RBC 
TF 
 Perianal abscesses, Candidiasis NA Y 2,3,16 
c.1537C>T 
p.R513X 
M 1 year, Sinusoidal obstruction syndrome (†) 
Severe bleeding 
tendency, CNS 
bleeding 
Platelet and RBC 
TF 
 Pulmonary aspergillosis Amphotericin B N 2,3,16 
c.1537C>T 
p.R513X 
M No HSCT 
Severe bleeding 
tendency 
Platelet and RBC 
TF 
 
Omphalitis, Fungemia (F. oxysporum), Soft 
tissue infection, Bacteremia (P. aeruginosa) 
(†) 
ATB therapy, Amphotericin 
B, flucytosine, granulocytes 
TF 
N 2,3,16 
c.1537C>T 
p.R513X 
M No HSCT 
Severe traumatic 
epistaxis (†) 
Platelet and RBC 
TF 
 Bacterial infections NA N 2,3,16 
c.1537C>T 
p.R513X 
M Yes 
Severe bleeding 
tendency, CNS 
bleeding 
Platelet and RBC 
TF 
 
Omphalitis, Perianal abscesses, CMV 
infections 
ATB therapy Y 2,3,16 
c.1537C>T 
p.R513X 
F No HSCT 
Moderate bleeding 
tendency 
Platelet and RBC 
TF 
 NA NA Y 2,3,16 
c.1537C>T 
p.R513X 
F No HSCT 
Moderate bleeding 
tendency 
Platelet and RBC 
TF 
 NA NA Y 2,3,16 
c.1537C>T 
p.R513X 
M No HSCT 
Moderate bleeding 
tendency 
 Mucocutaneous 
bleedings 
Platelet and RBC 
TF 
 Sepsis, CMV infection NA Y 2,3,16 
c.1537C>T 
p.R513X 
F No HSCT 
Hematuria, 
Gastrointestinal 
bleedings, Cutaneous 
bleedings 
RBC TF  Cutaneous ulcers, Cellulitis, Bacteremia NA Y 18 
c.1597C>T 
p.Q533X 
F 
5 months, MUD, RIC (Bu/Flu/TT), no GvHD, 
Good outcome 
Gastrointestinal 
bleedings, Vaginal 
bleedings 
Platelet and RBC 
TF 
 Presumed amnion infection ATB therapy Y 19 
 
FERMT3 variants were numbered according to the reference sequence NM_178443. The conditioning regimen intensity was defined as 
previously described.28 The affected families are separated using dotted lines. Abbreviations: †: death; ATB: antibiotic; ATG: anti-thymocyte 
globulin; Bu: busulfan; CMV: cytomegalovirus; CNS: central nervous system; Cy: cyclophosphamide; F: female; Flu: fludarabine; GvHD: graft 
versus host disease; HSCT: hematopoietic stem cell transplantation; Ig: immunoglobulin; M: male; MAC: myeloablative conditioning; Mel: 
melphalan; MMRD: mismatched related donor; MMUUCBD mismatched unrelated umbilical cord blood donor; MRD: matched related donor; 
MUD: matched unrelated donor; MUUCBD: matched unrelated umbilical cord blood donor; N: no; NA: not available; RBC: red blood cells; RIC: 
reduced intensity conditioning; RSV: respiratory syncytial virus; TF: infusion; TLNI: total lymph node irradiation; Treo: treosulfan; TT thiotepa; Y: 
yes.
c.1683-2A>G 
splice variant 
F Yes, Good outcome 
Antenatal CNS 
bleeding, Cutaneous 
bleeding 
Platelet TF, 
Tranexamic acid 
 Recurrent infections, Cutaneous ulcers 
ATB therapy, ATB 
prophylaxis 
Y 7,18,20 
c.1729C>T 
p.R577X 
M 
7 years, MUD, MAC (Bu/Flu/Cy/Rabbit ATG), 
GvHD (grade II), Good outcome 
Buccal bleedings, 
Epistaxis 
Platelet and RBC 
TF 
 
Recurrent infections, Pulmonary infections, 
bacteremia (S. pneumoniae) 
ATB therapy Y 21 
c.1729C>T 
p.R577X 
M 
3.5 years, MUD, MAC (Bu/Flu/Cy), Chronic 
lung GvHD (grade I) 
Mucosal bleedings NA  Recurrent infection, Pulmonary infections ATB therapy Y 21 
c.1729C>T 
p.R577X 
NA No HSCT 
Moderate bleeding 
tendency 
NA  NA NA Y 2,3 
c.1796A>C 
p.Q599P 
F No HSCT Mild bleeding tendency NA  
Recurrent pulmonary infections (A. 
baumanii, S mitis, E. coli), Bacteremia (P. 
aeruginosa), Mucocutaneous candidiasis, 
Intestinal infection (Salmonella), Urinary 
tract infection 
ATB therapy, Ig 
replacement therapy 
Y 22–24 
c.1802delA 
p.N601Mfs*? 
F 
2 months, MUUCBD, RIC (Flu/Treo/TT/rabbit 
ATG), Liver and skin GvHD (grade III) 
Cutaneous bleedings NA  Pulmonary candidiasis, CMV viremia NA Y 25 
c.1857delG 
p.A620Pfs*? 
NA 14 months, MUUCBD, good outcome 
Cutaneous bleeding, 
Epistaxis 
NA  Pneumocystis pulmonary infection NA Y 26,27 
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